Return to Clinical Trials Search Results

A Phase 3, Randomized, Double-blind, Multicenter Study of TSR-042 plus Carboplatin-Paclitaxel versus Placebo plus Carboplatin-Paclitaxel in Patients with Recurrent or Primary Advanced Endometrial Cancer

To compare the progression-free survival (PFS) of treatment with dostarlimab plus carboplatin-paclitaxel to treatment with placebo plus carboplatin-paclitaxel, as assessed by the Investigator per RECIST v.1.1, in the following: [ Time Frame: Up to 5 years ] * All subjects with recurrent or primary advanced endometrial cancer * Subjects with microsatellite instability-high (MSI-H) recurrent or primary advanced endometrial cancer

Phase

III

Recruitment Status

Current Studies